PeptiDREAM announces to form a joint venture to develop drugs for COVID-19
November 12, 2020, Kawasaki, Japan - This picture shows a logo of Japanese drug design venture PeptiDream at the company's headquarters in Kawasaki, suburban Tokyo on Thursday, November 12, 2020. PeptiDream announces the company will form a joint venture PeptiAID with four companies to development of the new drug for the treatment of COVID-19. PeptiDream developed PDPS technology to find peptide candidates targeting spike protein of coronavirus to enter human cells. PeptiAID will obtain PeptiDream's COVID-19 candidate compounds to enter clinical testing. (Photo by Yoshio Tsunoda/AFLO)